Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

AT9283

Product Specifications

UNSPSC Description

AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2].

Target Antigen

Apoptosis; Aurora Kinase; Autophagy; Bcr-Abl; FLT3; JAK

Type

Reference compound

Related Pathways

Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/at9283.html

Purity

99.70

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC=C(C=C4N3)CN5CCOCC5

Molecular Weight

381.43

References & Citations

[1]Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388.|[2]Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005.|[3]Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71Cancers (Basel). 2022 Mar 19;14(6):1575.|Harvard Medical School LINCS LIBRARY|J Adv Res. 2023 Mar 7;S2090-1232(23)00070-X.|Patent. US20180263995A1.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Front Oncol. 2021 Jun 18;11:656608.|PLoS Pathog. 2022 Jun 13;18(6):e1010620.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Product Datasheet

http://file.medchemexpress.com/batch_PDF/HY-50514/AT9283-DataSheet-MedChemExpress.pdf

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-50514/AT9283-SDS-MedChemExpress.pdf

Clinical Information

Phase 3

CAS Number

896466-04-9

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Kukoamine B Impurity 23
RM-K211123-01 10 mg

Kukoamine B Impurity 23

Ask
View Details
Kukoamine B Impurity 23
RM-K211123-02 25 mg

Kukoamine B Impurity 23

Ask
View Details
Kukoamine B Impurity 23
RM-K211123-03 50 mg

Kukoamine B Impurity 23

Ask
View Details
Kukoamine B Impurity 23
RM-K211123-04 100 mg

Kukoamine B Impurity 23

Ask
View Details
Rabbit Anti-Human LPL pAb
PA9943-01 50 μL

Rabbit Anti-Human LPL pAb

Ask
View Details
Rabbit Anti-Human LPL pAb
PA9943-02 100 μL

Rabbit Anti-Human LPL pAb

Ask
View Details